Email

The Race for A COVID-19 Vaccine Is Speeding Up

0 | By Alex Kagin

July 4 is one of my favorite holidays, and living in D.C., the excitement is intensified as a huge parade marches through the city and the night concludes at the National Mall with fireworks.

But this year will be very different.

Fireworks in the nation’s capital will take place in some form with many people watching from home and the National Independence Day Parade has been cancelled. The rest of the country is also still affected by COVID-19.

Gatherings are still limited, sports have not started back up in earnest, and many restaurants are still closed as they cannot operate profitably at limited capacity. We could be in for a situation where life will not go back to normal until we get a vaccine.

Cases are now right around 10 million and the number doesn’t seem to be slowing down, especially as more testing is done.

While deaths have decreased, it’s important to note that many people who got COVID-19 could live with the after effects their entire lives. Thousands of people could actually have to go back to the hospital because doctors are concerned that people could have lung scarring, known as pulmonary fibrosis, which is an irreversible condition with symptoms including shortness of breath and fatigue.

But we are also learning so much more about the disease as cases rise.

Just this last week, I learned that your risk of severe COVID-19 may be affected by blood type. A recent genetic study published in the New England Journal of Medicine found that people with blood type A were 45% more likely than people with other blood types to experience severe COVID-19 symptoms and respiratory failure.

That’s good information to have as 37% of the U.S. population has type A blood.

And speaking of positive news…

Pharmaceutical and biotech companies of all sizes continue spending billions on research and development to get a vaccine as quickly and safely as possible. We talked about Eli Lilly and Co. (LLY) and Johnson & Johnson (JNJ) last week as major pharmaceutical companies take action. We now have more players stepping in.

Sanofi (SNY) just announced that they will spend $1.9 billion to deliver a COVID-19 vaccine by mid-2021 using the messenger RNA technology of biotech company Translate Bio Inc. (TBIO) . This is similar to the technology that is being used in clinical trials from Moderna Inc. (MRNA) and Pfizer Inc. (PFE).

Trials are also ongoing from many other companies. Oxford University has started human clinical trials for a coronavirus vaccine in Brazil, which is supported by AstraZeneca PLC (AZN).

And these efforts are only scratching the surface. There’s a particular group of smaller vaccine innovators Michael believes have the absolute best chance of stopping this pandemic in its tracks, and they could generate huge profits while they do it.

It’s a topic that he’s been looking into, and he’s ready to share his research with you. Just click here to check it out.

Leave a Reply

Your email address will not be published. Required fields are marked *